These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1240 related articles for article (PubMed ID: 23253719)
1. Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma. Zheng D; Li J; Huang BH; Liu JR; Zou WY; Su C Chin Med J (Engl); 2012 Dec; 125(24):4454-9. PubMed ID: 23253719 [TBL] [Abstract][Full Text] [Related]
2. Two cycles of the PS-341/bortezomib, adriamycin, and dexamethasone combination followed by autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients. Lee JH; Lee JH; Kim DY; Kim SD; Choi Y; Kang YA; Seol M; Lee KH Eur J Haematol; 2012 Jun; 88(6):478-84. PubMed ID: 22364526 [TBL] [Abstract][Full Text] [Related]
3. [The efficacy and safety of bortezomib-based induction regimen before autologous hematopoietic stem cell transplantation in patients with multiple myeloma]. Li J; Liu JR; Huang BH; Chen M; Zheng D; Xu DR; Zou WY Zhonghua Nei Ke Za Zhi; 2012 Apr; 51(4):279-83. PubMed ID: 22781947 [TBL] [Abstract][Full Text] [Related]
4. Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma. Sahebi F; Frankel PH; Farol L; Krishnan AY; Cai JL; Somlo G; Thomas SH; Reburiano E; Popplewell LL; Parker PM; Spielberger RT; Kogut NM; Karanes C; Htut M; Ruel C; Duarte L; Murata-Collins JL; Forman SJ Biol Blood Marrow Transplant; 2012 Mar; 18(3):486-92. PubMed ID: 22198542 [TBL] [Abstract][Full Text] [Related]
5. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma. Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251 [TBL] [Abstract][Full Text] [Related]
6. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial. Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621 [TBL] [Abstract][Full Text] [Related]
7. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma. Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425 [TBL] [Abstract][Full Text] [Related]
8. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study. Kaufman JL; Nooka A; Vrana M; Gleason C; Heffner LT; Lonial S Cancer; 2010 Jul; 116(13):3143-51. PubMed ID: 20564642 [TBL] [Abstract][Full Text] [Related]
9. [Bortezomib plus dexamethasone treatment followed by reduced-intensity allogeneic stem cell transplantation for multiple myeloma refractory to high-dose chemotherapy with autologous transplantation]. Hayashi T; Yasui H; Kawakami K; Ikeda H; Takahashi F; Kobayashi T; Nishimura S; Ishida T; Imai K; Shinomura Y Rinsho Ketsueki; 2011 Mar; 52(3):136-41. PubMed ID: 21471701 [TBL] [Abstract][Full Text] [Related]
10. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Harousseau JL; Attal M; Leleu X; Troncy J; Pegourie B; Stoppa AM; Hulin C; Benboubker L; Fuzibet JG; Renaud M; Moreau P; Avet-Loiseau H Haematologica; 2006 Nov; 91(11):1498-505. PubMed ID: 17043025 [TBL] [Abstract][Full Text] [Related]
11. Thalidomide, cyclophosphamide and dexamethasone induction therapy: feasibility for myeloma patients destined for autologous stem cell transplantation. Chang WJ; Kang ES; Lee ST; Kim SH; Kim DW; Kim SJ; Kim K Acta Haematol; 2014; 132(2):226-32. PubMed ID: 24732093 [TBL] [Abstract][Full Text] [Related]
12. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670 [TBL] [Abstract][Full Text] [Related]
13. [Bortezomib-based induction therapy followed by autologous hematopoietic stem cell transplantation in multiple myeloma]. Huang B; Li J; Liu J; Gu J; Zheng D; Xu D; Zou W; Wang H Zhonghua Nei Ke Za Zhi; 2014 Nov; 53(11):865-72. PubMed ID: 25586356 [TBL] [Abstract][Full Text] [Related]
14. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Cavo M; Tacchetti P; Patriarca F; Petrucci MT; Pantani L; Galli M; Di Raimondo F; Crippa C; Zamagni E; Palumbo A; Offidani M; Corradini P; Narni F; Spadano A; Pescosta N; Deliliers GL; Ledda A; Cellini C; Caravita T; Tosi P; Baccarani M; Lancet; 2010 Dec; 376(9758):2075-85. PubMed ID: 21146205 [TBL] [Abstract][Full Text] [Related]
15. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation. Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH; Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634 [TBL] [Abstract][Full Text] [Related]
16. [Outcome of bortezomib plus chemotherapy with or without stem cell transplantation for treatment of multiple myeloma]. Wang YF; Deng SH; Wu T; Xu Y; Zou DH; Wang Y; Zhao YZ; Qiu LG Zhonghua Xue Ye Xue Za Zhi; 2008 Jun; 29(6):397-400. PubMed ID: 19031743 [TBL] [Abstract][Full Text] [Related]
17. Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma. Ludwig H; Viterbo L; Greil R; Masszi T; Spicka I; Shpilberg O; Hajek R; Dmoszynska A; Paiva B; Vidriales MB; Esteves G; Stoppa AM; Robinson D; Ricci D; Cakana A; Enny C; Feng H; van de Velde H; Harousseau JL J Clin Oncol; 2013 Jan; 31(2):247-55. PubMed ID: 23091109 [TBL] [Abstract][Full Text] [Related]
18. Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma. Badros A; Goloubeva O; Fenton R; Rapoport AP; Akpek G; Harris C; Ruehle K; Westphal S; Meisenberg B Clin Lymphoma Myeloma; 2006 Nov; 7(3):210-6. PubMed ID: 17229337 [TBL] [Abstract][Full Text] [Related]
19. [Effect of bortezomib on the efficiency of hematopoietic stem cell mobilization in patients with multiple myeloma]. Pokrovskaia OS; Mendeleeva LP; Urnova ES; Gaponova TV; Gal'tseva IV; Kuz'mina LA; Akhundova FM; Kalinin NN; Gretsov EM; Parovichnikova EN; Savchenko VG Ter Arkh; 2012; 84(7):35-41. PubMed ID: 23038970 [TBL] [Abstract][Full Text] [Related]
20. Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma. Bensinger WI; Jagannath S; Vescio R; Camacho E; Wolf J; Irwin D; Capo G; McKinley M; Potts P; Vesole DH; Mazumder A; Crowley J; Becker P; Hilger J; Durie BG Br J Haematol; 2010 Feb; 148(4):562-8. PubMed ID: 19919652 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]